Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 9349507
Knippschild U, et al. (1997) p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene 15, 1727-36 9349507
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S7-p - p53 (mouse)
Modsite: _MTAMEEsQSDISLE SwissProt Entrez-Gene
Orthologous residues
p53 (human): P4‑p, p53 iso2 (human): P4‑p, p53 iso4 (human): , p53 (mouse): S7‑p, p53 iso2 (mouse): S7‑p, p53 (rat): S4‑p, p53 (rabbit): S4‑p, p53 (green monkey): P4‑p
Characterization
Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, phosphopeptide mapping
Relevant cell lines - cell types - tissues:  COS (fibroblast), SV3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CK1D (human)
KINASE CK1E (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1E (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
KINASE CK1D (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IC261 decrease

S9-p - p53 (mouse)
Modsite: TAMEESQsDISLELP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S6‑p, p53 iso2 (human): S6‑p, p53 iso4 (human): , p53 (mouse): S9‑p, p53 iso2 (mouse): S9‑p, p53 (rat): S6‑p, p53 (rabbit): S6‑p, p53 (green monkey): S6‑p
Characterization
Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, phosphopeptide mapping
Relevant cell lines - cell types - tissues:  COS (fibroblast), SV3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CK1E (human)
KINASE CK1D (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1D (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
KINASE CK1E (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IC261 decrease

S12-p - p53 (mouse)
Modsite: EESQSDIsLELPLSQ SwissProt Entrez-Gene
Orthologous residues
p53 (human): S9‑p, p53 iso2 (human): S9‑p, p53 iso4 (human): , p53 (mouse): S12‑p, p53 iso2 (mouse): S12‑p, p53 (rat): S9‑p, p53 (rabbit): S9‑p, p53 (green monkey): S9‑p
Characterization
Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, immunoprecipitation, phosphopeptide mapping
Relevant cell lines - cell types - tissues:  COS (fibroblast), SV3T3 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  mouse, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CK1E (human)
KINASE CK1D (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK1E (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
KINASE CK1D (human) pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IC261 decrease